Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Treating sickle cell disease: Is hydroxyurea right for you?
source: The Pacific Sickle Cell Regional Collaborative
year: 2016
summary/abstract:Sickle cell disease changes the shape and texture of hemoglobin, which is a protein in red blood cells. People with sickle cell disease have hemoglobin that makes red blood cells a different shape.
The banana-shape of sickle cells block blood flow, which can cause:
– Pain
– Damage to organs, muscles, and tissues
– Sticky blood and damage to blood vessels due to:
Too many platelets (cells that help us stop bleeding when we get hurt),
Too many white blood cells (cells that protect us against infections).
Hydroxyurea (HU) is a medicine that treats sickle cell disease. It can’t cure you of sickle cell disease, but it can help you feel better if you take it every day and can help you stay healthy as you grow older.
Research shows people who take Hydroxyurea:
– Live longer and have less pain
– Need fewer blood transfusions and hospital stays
– Have fewer cases of acute chest syndrome
– Have less damage to their brain, lungs, kidneys, and spleen
read more
+myBinderRelated Content
-
Crizanlizumab for the Prevention of Pain Crises in Sickle Cell DiseaseBACKGROUND: The up-regulation of P-selec...
-
Hydroxyurea improves lung function in children with sickle cell diseaseFor the first time, researchers were abl...
-
The Association Between Timely Opioid Administration and Hospitalization in Children With Sickle Cell Disease Presen...Objective: To evaluate the association ...
-
Statement on NHLBI Decision to Pause the Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for Si...bluebird bio, Inc. suspended its clinica...
-
Alabama Man Free of Sickle Cell After Gene Therapyhttps://www.youtube.com/watch?v=E9vYON8D...
-
Sickle Cell Anemia Toddlers Benefit from Maximal Hydroxyurea Doses, Study FindsIntensifying treatment with hydroxyurea ...
-
GBT announces positive top-line data from part A of the phase 3 HOPE study of Voxelotor in sickle cell diseaseGlobal Blood Therapeutics, Inc. today an...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.